Incyte Corp.

NASDAQ:INCY  
65.55
-0.23 (-0.35%)
Products

Incyte Announces FDA Approval Of Jakafi For Treatment Of Chronic Graft-Versus-Host Disease

Published: 09/22/2021 16:56 GMT
Incyte Corp. (INCY) - Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-versus-host Disease (gvhd).